Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 76

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 76
---
31, 2024.

On September 26, 2024, we granted 4,167 options
to purchase shares of common stock at a per share exercise price of $6.85 to Kristen Landon, our Chief Commercial Officer, which vest
in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024.

On January 2, 2025, we granted a total of 120,000
options to purchase shares of common stock at a per share exercise price of $6.55 to Geoff Dow, our Chief Executive Officer, (105,000
common stock options) and Tyrone Miller, our Chief Financial Officer (15,000 common stock options), which vest in five equal tranches.
The first tranche was fully vested on the date of grant and thereafter, the options vest on the last date of each fiscal year beginning
December 31, 2025.

(d) Issuance of Notes.

None.

(e) Preferred Stock.

| ● | On                                                                                                                                    
 July 14, 2023, we converted the accumulated interest from the debt owed to Knight into 80,965 shares of our Series A Preferred Stock, 
 of which were issued to Knight.                                                                                                       |

The issuance of shares of Series A Preferred Stock
listed above was deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in
that the issuance of securities did not involve a public offering.

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits: Reference is made
to the Exhibit Index following Item 17 of Part II hereto, which Exhibit Index is hereby incorporated into this Item.

(b) Financial Statement Schedules: All schedules are omitted because the required information is inapplicable or the information is presented in the
financial statements and the related notes.

<div align='center'>II-4</div>

Item 17. Undertakings.

The undersigned registrant hereby undertakes:

(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required
by section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

(ii) To reflect in the prospectus any
facts or events arising after the effective date of the registration statement (or the most recent post